22. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB (2011) Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 1215: 150–160. 23. Singh NP, Singh UP, Hegde VL, Guan H, Hofseth L, et al. (2011) Resveratrol (trans-3,5,49-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-kappaB. Mol Nutr Food Res 55: 1207–1218. 24. Osmond GW, Augustine CK, Zipfel PA, Padussis J, Tyler DS (2012) Enhancing Melanoma Treatment with Resveratrol. J Surg Res 172: 109–115. 25. Gatouillat G, Balasse E, Joseph-Pietras D, Morjani H, Madoulet C (2010) Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J Cell Biochem 110: 893–902. 26. Guan H, Nagarkatti PS, Nagarkatti M (2007) Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma. J Immunol 179: 3715–3723. 27. McKallip RJ, Fisher M, Do Y, Szakal AK, Gunthert U, et al. (2003) Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem 278: 43818–43830. 28. Mustafa A, McKallip RJ, Fisher M, Duncan R, Nagarkatti PS, et al. (2002) Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. J Immunother 25: 476–488. 29. Rafi AQ, Zeytun A, Bradley MJ, Sponenberg DP, Grayson RL, et al. (1998) Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J Immunol 161: 3077–3086. 30. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, Nagarkatti P (2007) Resveratrol (trans-3,5,49-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72: 1508–1521. 31. Zhao Y, Yang J, Liao W, Liu X, Zhang H, et al. (2010) Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 12: 665–675. Resveratrol in IL-2 Therapy against Melanoma 32. Medema RH, Jaattela M (2010) Cytosolic FoxO1: alive and killing. Nat Cell Biol 12: 642–643. 33. Singh UP, Singh NP, Singh B, Hofseth LJ, Taub DD, et al. (2012) Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(-/-) mice. Brain Behav Immun 26: 72–82. 34. Yang Y, Paik JH, Cho D, Cho JA, Kim CW (2008) Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. Int Immuno- pharmacol 8: 542–547. 35. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, et al. (2008) Tumor- induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor- draining lymph nodes. J Immunol 181: 3291–3300. 36. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233–4244. 37. Donskov F, Bennedsgaard KM, Hokland M, Marcussen N, Fisker R, et al. (2004) Leukocyte orchestration in blood and tumour tissue following interleukin- 2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 53: 729–739. 38. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, et al. (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69: 1553–1560. 39. Kusmartsev S, Gabrilovich DI (2005) STAT1 signaling regulates tumor- associated macrophage-mediated T cell deletion. J Immunol 174: 4880–4891. 40. Narita Y, Wakita D, Ohkur T, Chamoto K, Nishimura T (2009) Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed Res 30: 7–15. PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e35650